GLOBAL THERAPEUTIC VACCINES MARKET 2014 - 2019 Market Shares, Forecasts & Trends
mordorintelligence.com
VIEW THIS REPORT ON OUR WEBSITE
TABLE OF CONTENTS 1. Introduction
1
1.1 Overview
1
1.2 Market Definition
2
1.3 Market Trends
3
2. Executive Summary
4
3. Global Therapeutic Proteins Market – Industry Analysis
5
3.1 Market Drivers
5
3.1.1 Increasing demand ,higher onset of diseases
5
3.1.2 Government funded projects and associations
6
3.1.3 Higher profitability and improved technology
6
3.2 Market opportunities 3.2.1 New Target populations- shift from established markets to lesser
7 8
developed markets 3.3 Market Constraints 3.3 .1 Risk of adverse effects 3.3.3 High regulatory Intervention and cost
4. Types of Vaccines
9 9 10
11
I. Live, attenuated vaccines
11
II. Inactivated vaccines
12
III. Subunit vaccines
13
IV. Toxoid vaccines
14
V. Conjugate vaccines
15
VI. DNA vaccines
16
Global Therapeutic Vaccines Market | Sample
VIEW THIS REPORT ON OUR WEBSITE
VII. Recombinant vector vaccines
5. Vaccine market by application ( Market Size , Forecast, CAGR) 5.1 Pediatric Vaccines
16
17 17
5.1.1 Pneumococcal
18
5.1.2 Varicella
19
5.1.3 Combinations
20
5.1.3.1 Bivalent
20
5.1.3.2 Trivalent
21
5.1.3.3 Tetravalent
21
5.1.3.4 Pentavalent
22
5.1.4 MMR
23
5.1.5 Poliovirus
24
5.1.6 Hepatitis
25
5.1.7 HIB
26
5.1.8 Other Pediatric
26
5.2 Adult Vaccines
27
5.2.1 Influenza
27
5.2.2 Cervical Cancer
28
5.2.3 Hepatitis
29
5.2.4 Zoster
29
5.2.5 Other adult vaccines
30
6. Regional Analysis of the Vaccine market
31
6.1 North America (Market Size, Forecast and CAGR)
31
6.1.1 USA
31
6.1.2 Canada
32
Global Therapeutic Vaccines Market | Sample
VIEW THIS REPORT ON OUR WEBSITE
6.1.3 Rest of north America
33
6.2 Europe (Market Size, Forecast and CAGR)
34
6.2.1 Germany
34
6.2.2 France
35
6.2.3 UK
36
6.2.4 Italy
37
6.2.5 Spain
38
6.2.6 Rest of Europe
39
6.3 Asia Pacific (Market Size, Forecast and CAGR)
40
6.3.1 China
40
6.3.2 India
41
6.3.3 Japan
42
6.3.4 Rest of Asia
43
6.4 Rest of the World(Market Size, Forecast and CAGR)
7. Competitive Landscape
44
45
7.1 Current Market trends In Vaccines
45
7.2 Future of Vaccines
46
7.3 Joint Ventures
47
7.4 Mergers and Acquisitions
48
7.5 PentAct HIB, Quinvaxem and the future of Pentavalent vaccines
49
8. Key Company Profiles
50
8.1 SanofiAvnetis
51
8.2 Merck
52
8.3 Glaxosmithkline
53
8.4 Novartis
54
Global Therapeutic Vaccines Market | Sample
VIEW THIS REPORT ON OUR WEBSITE
8.5 Pfizer
55
8.6 Serum institute
56
9. List Of tables
57
10. List of Figures
58
11. Appendix
59
Global Therapeutic Vaccines Market | Sample
VIEW THIS REPORT ON OUR WEBSITE
RESEARCH METHODOLOGY 1)
Secondary Research: Information was collected from a number of public and paid data sources. Public
sources involved Government websites, publications from the therapeutic vaccine programs of different countries, company annual reports, white papers and research publications by recognized industry experts, WHO, Food and drug administration, National cancer Institute, Clinical trials.gov. Paid data sources include authentic industry databases.
2)
Primary Research: After collecting data from secondary sources, primary interviews were conducted with
stakeholders at different points of therapeutic vaccines manufacturers, distributors, ingredient suppliers, companies manufacturing therapeutic vaccines and key opinion leaders of the industry. 50 respondents constituting therapeutic vaccines manufacturers, distributors, suppliers, hospital administrators, etc. were interviewed. The data collected from the survey was analyzed by an expert team of analysts to both validate the data points obtained from secondary research and to fill any gaps in data.
3)
Market Analysis: The market analysis phase involves analyzing the collected data, market breakdown
and forecasting. Macroeconomic indicators and bottom-up and top-down approaches are used to arrive at a complete set of data points that give way to valuable qualitative and quantitative insights. Each data point is verified by the process of data triangulation to validate the numbers and arrive at a close estimate.
4)
Expert Validation: The market analysis data is verified and validated by a number of experts, both in-
house and external.
5)
Report Writing: After the data is curated through the process, our analysts begin to write the report.
Garnering insights from data and forecasts, insights are drawn to visualize the entire business ecosystem in a single report.
Global Therapeutic Vaccines Market | Sample
VIEW THIS REPORT ON OUR WEBSITE
OVERVIEW The vaccine market accounts for a relatively small share (2-3%) of the global pharmaceutical market sales. However, there has been rapid growth over recent years, with the vaccine market quadrupling in value from USD 5 billion in 2000 to almost USD 24 billion in 2013. Once a commodity market with low margins, the vaccines on the market now include blockbusters and mega blockbusters. New candidates for vaccinating against cancers and HIV are also projected to hit the magic milestone.
Multinational vaccine companies historically have conducted much of the innovation, research, and development in the field of vaccine production. They have used significant revenues, global size, and deeper expertise to fund. The development of new technologies for vaccine development – an expensive and relatively time consuming process. But Despite the success of vaccines, infectious diseases are still a major cause of illnesses worldwide and at least 40 major infectious diseases are still uncontrolled by vaccination.
There are currently close 120 new vaccines in the pipeline of various companies across the globe set to hit the market in the next 5 years to come. In anticipation of this and with the emergence of new target market and smaller player into the market, the Global vaccine market is set to grow by a CAGR of close to 12.4 % till the year 2020.
Global Vaccine sales( $ billion) 30
Billions
25 20
DATA HIDDEN FROM VIEW
15
10 5 0 2000
2006 Source: Mordor Intelligence Analysis
Global Therapeutic Vaccines Market | Sample
2013
VIEW THIS REPORT ON OUR WEBSITE
MARKET DEFINITION
The vaccine Market is different from any other Commodity Market. Compared to the pharmaceutical market it is relatively small, although growing fast. The vaccine market is rather concentrated on both supply and demand sides. It is highly regulated and largely dependent on public purchasers and donor policies. The vaccine market has very distinct features which increase the complexity of assessing and understanding pricing and procurement in their context. It is made up of individual markets for individual vaccines or vaccine types, each with their own specificities, particularly on the supply side.
The vaccine market accounts for a relatively small share (2-3%) of the global pharmaceutical market sales. However, there has been rapid growth over recent years, with the vaccine market quadrupling in value from USD 5 billion in 2000 to almost USD 24 billion in 2013, according to various sources. The market is expected to grow at a CAGR of 12.4% till 2020, with the arrival of new preventive, therapeutic and adult vaccines.
The market is dominated by 5 major players with Sanofi Pasteur, GSK, Merck, Pfizer, and Novartis being the top contenders in the market.
Global Vaccine Majors
MERCK Pfizer
Source: company websites
Global Therapeutic Vaccines Market | Sample
VIEW THIS REPORT ON OUR WEBSITE
VACCINE MARKET BY APPLICATION (MARKET SIZE, FORECAST, CAGR)
PEDIATRIC VACCINES
Pneumococcal Vaccines Pneumococcal disease is caused by Streptococcus pneumoniae, a bacterium that has more than 90 serotypes. Most serotypes cause disease, but only a few produce the majority of invasive pneumococcal disease. The 10 most common types cause 62% of invasive disease worldwide.
There are two major clinical syndromes of invasive pneumococcal disease: bacteremia, and meningitis. They are both caused by infection with the same bacteria, but have different manifestations. Pneumococcal pneumonia is the most common disease caused by pneumococcal infection. Pneumococcal pneumonia can occur in combination with bacteremia and/or meningitis, or it can occur alone. Isolated pneumococcal pneumonia is not considered invasive disease but it can be severe. It is estimated that 175,000 cases occur each year in the United States. The incubation period is short (1-3 days). Symptoms include abrupt onset of fever, shaking chills or rigors, chest pain, cough, shortness of breath, rapid breathing and heart rate, and weakness. The fatality rate is 5%-7% and may be much higher in the elderly. Pneumococcal disease kills more people in the United States each year than all other vaccine-preventable diseases combined. An estimated 36,850 cases and 4,250 deaths from invasive pneumococcal diseases (bacteremia and meningitis) occurred in the United States in 2011.
In 2000, the first pneumococcal conjugate vaccine (PCV) was licensed in the U.S. This vaccine contained seven serotypes (4, 6B, 9V, 14, 18C, 19F, and 23F) of Streptococcus pneumoniae and became known as PCV7 (Prevnar by Wyeth, now Pfizer). Ten years later in February 2010, a new 13-valent product was licensed — PCV13 (Prevnar 13, Pfizer) — which added 6 new serotypes (1, 3, 5, 6A, 7F, and 19A). Together, these 13 serotypes account for the majority of invasive pneumococcal disease (IPD) in the U.S., including serotype 19A, which is the most common IPD-causing serotype in young children.
Global Therapeutic Vaccines Market | Sample
VIEW THIS REPORT ON OUR WEBSITE
The Pneumococcal Vaccine market in 2012 was pinned to be close to $ 4 Billion and is estimated to grow to $8.5 billion by the year 2020. This is touted to be the fastest growing vaccine market in the world, forecasted to grow at a CAGR of 9.62% during the forecasted period.
Table 1: Pneumococcal Vaccine Market ($ millions) Region
2012
2013
2014
2020
CAGR
NA
XX
836
XX
XX
XX
Europe
1040
XX
XX
XX
XX
APAC
XX
XX
XX
2380
ROW
XX
XX
XX
XX
12
Global
XX
XX
XX
XX
XX
XX
Source: Mordor Intelligence Analysis
Figure 1
Pneumococcal Vaccines Market 9000 8000 $ Millions
7000 6000
DATA HIDDEN FROM VIEW
5000
4000 3000 2000 1000 0 2012
2013
2014
Source: Mordor Intelligence analysis
Global Therapeutic Vaccines Market | Sample
2020
VIEW THIS REPORT ON OUR WEBSITE
The Pneumococcal vaccine market is set to grow at a CAGR of 9.62% during the forecasted period. The APAC regions and the African regions in the Row are bound to see the maximum growth during this period, due to the increased acceptance and availability of the vaccine in these markets.
Global Therapeutic Vaccines Market | Sample
VIEW THIS REPORT ON OUR WEBSITE
DISCLAIMER Mordor Intelligence Reports and their contents, including all the analysis and research containing valuable market information, are provided to a select group of customers in response to orders. Our customers acknowledge when ordering that Mordor Intelligence strategic analysis services are for our customers’ internal use and not for general publication or disclosure to third parties.
Quantitative market information is based primarily on interviews and therefore, is subject to fluctuation. Mordor Intelligence takes no responsibility for any incorrect information supplied to us by manufacturers or users.
No part of this strategic analysis service may be given, lent, resold or disclosed to non-customers without written permission. Reproduction and/or transmission in any form and by any means including photocopying, mechanical, electronic, recording or otherwise, without the permission of the publisher is prohibited.
ABOUT US
Mordor Intelligence is a global market research and consulting firm. Our singular focus is to provide research insights for business success.
Our research team has expertise in diverse fields like Agriculture, Healthcare, ICT, Chemicals, Manufacturing, Logistics, Electronics and Automotive. However diverse the expertise maybe, everyone in our team shares one common trait - we love data and we love providing solutions to clients using that data even more. Seeing your business flourish based on our solutions and strategy is what we love the most. For information regarding permissions and sales, please contact: info@mordorintelligence.com
Global Therapeutic Vaccines Market | Sample
!
Mordor Intelligence LLP No. 30, Padma Nilaya, Chola Nagar Bangalore, Karnataka, India 560032 +1 781 881 1110 | info@mordorintelligence.com
Copyright Š 2014 Mordor Intelligence LLP All Rights Reserved. This document contains highly confidential information and is the sole property of Mordor Intelligence LLP. No part of it may be circulated, copied, quoted, or otherwise reproduced without the approval of Mordor Intelligence LLP.
7 | Mordor Intelligence
!